Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post‐transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study
- 29 November 2017
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 32 (2)
Abstract
Background: In 2012, an Italian Named Patient Program began for hepatitis C virus (HCV)‐infected liver transplant (LT) recipients with advanced fibrosis, before approval of direct antiviral agents (DAA), to benefit severely ill patients. The aim of this “real‐life” study was to assess treatment efficacy and safety with an extended course of daclatasvir (DCV) plus sofosbuvir (SOF) with or without ribavirin (RBV).Methods: All HCV LT recipients with severe fibrosis in 15 Italian transplant centers were treated with DCV+SOF±RBV for 24 weeks; sustained virological response was assessed at 12 weeks post‐treatment (SVR12).Results: Eighty‐seven patients were enrolled (75.9% males, mean age 58.4 ± 7.2 years, 83.9% genotype 1, 81.6% cirrhosis); 52 (59.8%) received RBV. Overall, 79 obtained SVR12 (90.8%): 100% in F3 and 88.7% in cirrhotics (91.5% in Child‐Pugh A, 83.3% in Child‐Pugh B and C). According to the treatment group, SVR was 80% in DCV + SOF group and 98.1% in SOF + DCV + RBV. Two virological relapses occurred during follow‐up in cirrhotic patients who received DCV + SOF. Four cirrhotic patients in DCV + SOF group and 1 in DCV + SOF + RBV group died on treatment.Conclusion: An extended course of SOF plus DCV for 24 weeks, with or without RBV, is effective and well tolerated for the treatment of post‐LT HCV recurrence with severe fibrosis.Keywords
This publication has 20 references indexed in Scilit:
- Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver TransplantationGastroenterology, 2015
- An Interferon-free Antiviral Regimen for HCV after Liver TransplantationNew England Journal of Medicine, 2014
- Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given lateDigestive and Liver Disease, 2014
- Progression of liver fibrosis in post-transplant hepatitis C: Mechanisms, assessment and treatmentJournal of Hepatology, 2013
- Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)Journal of Hepatology, 2012
- Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantationJournal of Hepatology, 2007
- Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis CHepatology, 2004
- Analysis of causes of death in liver transplant recipients who survived more than 3 yearsLiver Transplantation, 2001
- Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantationHepatology, 2000
- Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patientsGastroenterology, 1997